Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

SEQUANA MEDICAL Stock Bullish Momentum With A 10.69% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with SEQUANA MEDICAL (SEQUA.BR) jumping 10.69% to €1.78 on Wednesday, after two consecutive sessions in a row of gains. BEL 20 rose 1.52% to €4,029.25, after two successive sessions in a row of losses, on what was an all-around up trend trading session today.

SEQUANA MEDICAL's last close was €1.61, 66.8% under its 52-week high of €4.85.

About SEQUANA MEDICAL

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.32.

Moving Average

SEQUANA MEDICAL's value is above its 50-day moving average of €1.72 and way below its 200-day moving average of €2.85.

Volatility

SEQUANA MEDICAL's last week, last month's, and last quarter's current intraday variation average was 3.58%, 0.45%, and 3.71%.

SEQUANA MEDICAL's highest amplitude of average volatility was 3.58% (last week), 2.02% (last month), and 3.71% (last quarter).

More news about SEQUANA MEDICAL (SEQUA.BR).